Faculty Opinions recommendation of Treatment of endometriosis-related chronic pelvic pain with Ulipristal Acetate and associated endometrial changes.

Edgardo Rolla
In: Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · 2019 · doi:10.3410/f.735134387.793557767 · W4251392956
OA: green CC0
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-12 ⓘ

This faculty opinion recommends ulipristal acetate for treating endometriosis-related chronic pelvic pain, noting that aberrant progesterone signaling is a shared pathway in fibroids and endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Background: Aberrant progesterone signaling has been demonstrated in mechanistic studies to be a shared common pathway in fibroids and endometriosis. Progesterone receptor modulation with the selective progesterone receptor modulator (SPRM) ulipristal may decrease pain associated with endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_pain

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (7)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK